Trials / Terminated
TerminatedNCT04842630
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors
An Open-Label, Multicenter, Dose Escalation And Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SHR-1916 in adult patients with locally advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1916 | All participants receive SHR-1906 alone |
Timeline
- Start date
- 2021-04-08
- Primary completion
- 2022-11-01
- Completion
- 2022-11-01
- First posted
- 2021-04-13
- Last updated
- 2024-02-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04842630. Inclusion in this directory is not an endorsement.